ProSpective multIcenter observationaL Study on the Quality of Life of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line of Treatment
Phase of Trial: Phase IV
Latest Information Update: 14 Apr 2018
At a glance
- Drugs Panitumumab (Primary) ; Cetuximab
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SILQ
- Sponsors Amgen
- 21 Apr 2017 Planned End Date changed from 1 Jun 2018 to 31 Dec 2019.
- 21 Apr 2017 Planned primary completion date changed from 1 Jun 2018 to 31 Dec 2019.
- 16 Jun 2016 Planned End Date changed from 1 Oct 2018 to 1 Jun 2018.